{
  "id": 7337209,
  "title": "Patient-derived ascites reveals functional advantages of γδCAR T-cells within the ovarian cancer-like tumor microenvironment",
  "url": "https://urgent.news/2026/09/14/patient-derived-ascites-reveals-functional-advantages-of-car-t-cells",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.08.749386v1?rss=1"
  },
  "original_language": "en",
  "account": "Chimeric antigen receptor (CAR) cells derived from {gamma}{delta} T-cells have shown limited clinical benefit when treating solid tumors like ovarian cancer (OVCA). While {gamma}{delta} T-cells can detect malignant transformation and cause cytotoxicity, these traits have led to impressive preclinical efficacy, but limited therapeutic activity. The reasons behind this difference are still unclear.\n\nIn this study, researchers created an ex-vivo culture using highly inflammatory patient-derived malignant ascites and hypoxic conditions to replicate the tough challenges that CAR T-cells face in the immunosuppressive OVCA tumor microenvironment. They found that CAR-expressing {gamma}{delta} T-cells were present within conventional (conv)CAR T-cells, and these cells showed better proliferative capacity compared to {gamma}{delta}neg T-cells.\n\nNext, the researchers produced {gamma}{delta}CAR T-cells for comparison with convCAR T-cells, examining differences in gene expression and functionality. In the TME-like conditions, {gamma}{delta}CAR T-cells had lower viability but consistently outperformed convCAR T-cells. They had more favorable gene expression profiles, stronger cytotoxicity, better retention of cytokine secretion and degranulation, and higher proliferative capacity.\n\nInterestingly, the same protein profile in ascites affected the viability of both cell types similarly. Overall, these findings show that {gamma}{delta}CAR T-cells have specific functional advantages over convCAR T-cells in the immunosuppressive OVCA TME-like condition while dealing with different cellular fitness constraints. This research provides valuable insights into the potential use and limitations of {gamma}{delta}CAR T-cells in treating ovarian cancer.",
  "summary": "Chimeric antigen receptor (CAR) T-cells engineered from {gamma}{delta} T-cells show limited clinical benefit in solid tumors such as ovarian cancer (OVCA). Although {gamma}{delta} T-cells can detect malignant transformation and exert cytotoxicity, these properties confer potent preclinical efficacy but limited therapeutic activity and the basis for this discrepancy remains unclear. Here, we…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}